-

RAFAEL HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Rafael Holdings, Inc. - RFL

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rafael Pharmaceuticals, Inc. (“Pharma”) to Rafael Holdings, Inc., (“the Company”) (NYSE: RFL). Under the terms of the proposed transaction, Pharma shareholders will receive Holdings Class B common stock amounting to approximately 48% of the currently outstanding capitalization of the company. Additional equity in the company is expected to be issued in connection with anticipated financing and employment agreements, which will reduce the foregoing percentage proportionately. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.

If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-rfl/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn
KSF Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857

Industry:

Kahn Swick & Foti, LLC

NYSE:RFL
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn
KSF Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857

More News From Kahn Swick & Foti, LLC

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequ...

Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Assertio Holdings, Inc. (NasdaqCM: ASRT) to Garda Therapeutics. Under the terms of the proposed transaction, shareholders of Assertio will receive $18.00 per share in cash and a contingent value right. KSF is seeking to determine whether this consideration and the process that led to it are adequate,...

UniFirst Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of UniFirst Corporation - UNF

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of UniFirst Corporation (NYSE: UNF) to Cintas Corporation (NasdaqGS: CTAS). Under the terms of the proposed transaction, shareholders of UniFirst will receive $155.00 in cash and 0.7720 shares of Cintas stock for each share of UniFirst that they own. KSF is seeking to determine whether this considerati...
Back to Newsroom